The tumor suppressor function of CYLD in skin is due to the reduced proliferation rate mainly through a delay in the G1 to S phase transition by reducing cyclin D1 expression levels [2], [10], [31] in a NF-κB dependent signaling pathway. Here, CYLD is linked to neoplasm.